Pulse Biosciences, Inc.
PLSE Nasdaq
SEC CIK 1625101
Follow Pulse Biosciences
Weekly email: filings, results
Revenue, last quarter
$395K
+359.3% vs same quarter last year
Net income
−$23.1M
−18.9% vs same quarter last year
EPS, diluted
−$0.32
−10.3% vs same quarter last year
Operating cash flow
−$15.3M
−17.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $350K | −$72.8M |
| FY24 | $0 | −$53.6M |
| FY23 | $0 | −$42.2M |
| FY22 | $700K | −$58.5M |
| FY21 | $1.4M | −$63.7M |
| FY20 | $0 | −$49.9M |
| FY19 | - | −$47M |
| FY18 | - | −$37.5M |
| FY17 | - | −$25.6M |
| FY16 | - | −$9.5M |
| FY15 | - | −$2.8M |
| FY14 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −21982.6% | −20794.6% |
| FY24 | - | - |
| FY23 | - | - |
| FY22 | −8293.9% | −8357.9% |
| FY21 | −4443.9% | −4489.4% |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
| FY15 | - | - |
| FY14 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$54.4M |
| FY24 | −$36.5M |
| FY23 | −$33.2M |
| FY22 | −$47.4M |
| FY21 | −$54.5M |
| FY20 | −$35.8M |
| FY19 | −$34.8M |
| FY18 | −$24.2M |
| FY17 | −$13.6M |
| FY16 | −$8.1M |
| FY15 | −$3.4M |
| FY14 | - |
- Pulse Biosciences
- Healthcare median
Show the numbers
| Year | Pulse Biosciences | Healthcare median |
|---|---|---|
| FY25 | −20794.6% | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | −8357.9% | −80.4% |
| FY21 | −4489.4% | −71.9% |
| FY20 | - | −62.2% |
| FY19 | - | −46.3% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −38.4% |
| FY14 | - | −35.5% |